Adaptive Biotechnologies Corporation announced that Palmetto GBA?s Molecular Diagnostics Program (MolDX) has finalized a local coverage determination (LCD) which supports the Medicare coverage for clonoSEQ? to detect and monitor minimal residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (ALL), multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). clonoSEQ is the first and only U.S. Food and Drug Administration (FDA)-cleared assay for MRD assessment in CLL, MM and ALL, and is widely available to clinicians and patients across the U.S. clonoSEQ leverages the power of NGS and offers an accurate and reliable way to assess how disease burden changes over time in response to treatment or during remission. When utilized as a series of tests throughout a patient?s journey with cancer, the assay can help clinicians predict long-term outcomes, assess treatment response, monitor disease burden and detect potential relapse. clonoSEQ has broad coverage in the U.S., with over 240 million covered lives across both Medicare and commercial payers.